Why the study?
The impact of cardiac myxomas on the immune response remains indefinite, despite laboratory tests and histological findings suggesting a correlation with inflammatory reaction.
Cardiac myxomas are associated with an inflammatory response, and preoperative NLR correlates with tumor size, suggesting its potential as a prognostic biomarker.
Inflammatory features in myxomas may inform prognosis; leaves open NLR as biomarker pending prospective validation.
INTRODUCTION: The impact of cardiac myxomas on the immune response is still indefinite, although laboratory tests and histological findings suggest that there is a correlation between myxomas and inflammatory reaction. OBJECTIVES: Our study speculates that cardiac myxomas are associated with inflammatory response and investigates potential elements of inflammation in the histopathological examination and biomarkers from laboratory tests. METHODS: It is a retrospective study and data were collected from a single center between May 2010 to May 2018. Autopsies and laboratory tests of 54 cases were analyzed. RESULTS: In 20,4% of the autopsies, inflammatory elements were identified. The neutrophil/lymphocyte ratio (NLR) preoperatively is elevated in patients suffering from cardiac myxoma while its value is correlated to the tumor size. CONCLUSIONS: Cardiac myxoma is an entity that affects the immune response of patients. The biomarker NLR could be utilized as a prognostic factor regarding enlarged cardiac myxomas. Future studies still need to be conducted in order to confirm the usefulness of this biomarker on cardiac myxomas.
No takes yet. Share an insight, caveat, or question.
Michopanou et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: